Table 1.
Baseline and clinical characteristics of the patients included in the study
| Variable | Characteristics |
|---|---|
| Age in years, median (IQR) | 45.00 (41–48) |
| Sex: male/female (% male) | 357/85 (80.8%) |
| Serum bilirubin (mg/dL), median (IQR) | 0.53 (0.37–0.84) |
| Serum creatinine (mg/dL), median (IQR) | 0.78 (0.69–0.91) |
| CD4 count <200 cells/µL, n (%) | 82 (18.6%) |
| Detectable HIV viral load (copies/mL), n (%) | 113 (25.6%) |
| HIV transmission mode, n (%) | |
| Injection drug use | 322 (72.9%) |
| Sexual | 120 (27.1%) |
| HIV/HCV co-infection, n (%) | 307 (69.5%) |
| Alcohol or drug use, n (%) | 158 (35.7%) |
| Co-morbidities, median (IQR) | 2.00 (1.00–3.00) |
| AIDS, n (%) | 297 (67.2%) |
| Type of HAART, n (%) | |
| 2 NRTI+1 NNRTI | 200 (45.2%) |
| 2 NRTI+1 PI | 238 (53.8%) |
| Others (including CCR5 antagonists or IntIn) | 44 (10.0%) |
| Adherence to HAART ≥90%, n (%) | 298 (67.4%) |
| Co-medications, median (IQR) | 2.00 (0.00–4.00) |
| Days of hospital stay, median (IQR) | 8.00 (5.00–12.75) |
| Hospital admissions the year before, minimum–maximum | 0–7 |
HAART, highly active antiretroviral treatment; IntIn, integrase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitors.